Picture loading failed.

Anti-C5 therapeutic antibody (Pre-made Ravulizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5).

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-472-1mg 1mg 3090
GMP-Bios-ab-472-10mg 10mg 21890
GMP-Bios-ab-472-100mg 100mg 148000
GMP-Bios-ab-472-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-C5 therapeutic antibody (Pre-made Ravulizumab biosimilar,Whole mAb)
INN Name Ravulizumab
TargetC5
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI Structure5i5k:HL:XY
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesAlexion Pharmaceuticals
Conditions ApprovedParoxysmal nocturnal haemoglobinuria
Conditions ActiveHaemolytic uraemic syndrome;Myasthenia gravis;IgA nephropathy
Conditions Discontinuedna
Development Techna